drugset / Trial / NCT07168837

Letrozole and Cabergoline Versus Letrozole Alone in Ovulation Induction

NCT07168837

Completed 100 enrolled Al-Azhar University
RandomizedParallel-groupDouble-blindTreatment

Summary

Polycystic Ovarian Syndrome (PCOS) is the most common endocrine disorders in women of reproductive age. According to the World Health Organization (WHO) estimation revealed over 116 million women (3.4%) are affected by PCOS worldwide. Owing to the intricacy of this condition, various sets of diagnostic criteria have been initiated for the confirmation of PCOS which are: National Institute of Health, Rotterdam's Criteria, Androgen Excess and PCOS society. The prevalence of PCOS is estimated at about 4 to 21 % when it is diagnosed according to the Rotterdam criteria accounting for 75% of cases with anovulatory infertility.

Timeline

Start
2023-01-10
Primary completion
2024-05-01
Completion
2024-05-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cabergoline Small molecule 0.5 mg
Comparator Letrozole Other / unclassified 5 mg Oral